Diagesil

Diagesil is an early-stage biotechnology company focused on developing rapid, high-sensitivity diagnostic tools for infectious diseases. The company utilizes a proprietary nanoparticle-based platform designed to detect bacterial pathogens and biomarkers directly from clinical samples without the need for lengthy culture processes. By significantly reducing the time to diagnosis, Diagesil aims to improve clinical outcomes in critical care settings, such as sepsis management, where rapid intervention is vital. Their technology integrates advanced materials science with molecular diagnostics to provide point-of-care solutions for healthcare providers.